Mindray Medical, a leading medical and biological company, has attracted substantial attention from overseas institutions in the past 10 days. According to statistics from the survey date deadline, a total of 124 overseas institutions have intensively surveyed Mindray Medical, marking it as the most scrutinized company among the 370 surveyed by institutions during this period.
The statistics, provided by Securities Times·Databao, reveal that securities companies accounted for the largest proportion of the surveying institutions, with 328 companies being extensively surveyed. Fund companies followed, with 292 companies under scrutiny, and 77 listed companies being interviewed by overseas institutions.
The overseas institutions’ survey shows that the stock prices of the companies they examined fell by an average of 1.74% during the 10-day period. However, some companies experienced a rise in their stock prices, with Tongda Chuangzhi and Jiulian Technology being the best performers, experiencing cumulative increases of 18.91% and 13.08%, respectively.
The survey included companies from various industries, such as light industrial manufacturing, household appliances, computer, and medical biotechnology. The stock prices of 50 companies dropped during the period, with Oya shares experiencing the largest decline of 24.96%.
It is important to note that the article serves as a news report and does not constitute investment advice. The stock market is risky, and investment should be approached cautiously. For those interested in staying updated on stock market trends and policy information, Securities Times recommends downloading their official APP or following their official WeChat account.